All In Biotech

Drug Trial Radar · NCT07619157

A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus

A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jun 2, 2026

Primary completion

Nov 30, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of ONO-3310 in healthy Japanese adult male subjects and chronic kidney disease patients with type 2 diabetes mellitus

Conditions

  • Type2 Diabetes Mellitus
  • Chronic Kidney Disease

Interventions

  • ONO-3310Drug

    Single oral dose of ONO-3310 to HV

  • PlaceboDrug

    Single oral dose of Placebo to HV

  • ONO-3310Drug

    Multiple oral dose of ONO-3310 to HV

  • PlaceboDrug

    Multiple oral dose of Placebo to HV

  • ONO-3310Drug

    Single or multiple oral dose of ONO-3310 to CKD patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventTime frame: Through study completion, typically 10days (HV single), 23 days (HV multiple), and 74 days (CKD)
  2. Maximum plasma observed concentration (Cmax)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
  3. Time to reach maximum observed concentration (Tmax)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
  4. Area under the plasma concentration versus time curve from time zero to 24 hours (AUC24h)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
  5. Area under the plasma concentration versus time curve from time zero to infinity (AUCinf)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
  6. Area under the plasma concentration versus time curve from time zero to time of last measurable concentration (AUClast)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
  7. Elimination half-life (T1/2)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
  8. Apparent total clearance (CL/F)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
  9. Urinary excretion rate of unchanged drugTime frame: Up to 6 days (HV single)
  10. Pharmacodynamics (evaluation of Urinary albumin-to-creatinine ratio)Time frame: Up to 74 days (CKD)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Souseikai Hakata Clinic

    Fukuoka, Fukuoka, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.